No shortages to deal with: The best part about semaglutide
DPP-4 inhibitors are also used therapeutically to enhance endogenous GLP-1 activity, but only for glycemic control, as they are weight-neutral
However, in the AWARD 7 trial, a dedicated 52-week trial of dulaglutide in patients with diabetic kidney disease, stage 3-4, the decline with time was significantly reduced compared with insulin glargine [29]
These users describe skin quality remaining noticeably superior to pre-treatment baseline even year post-discontinuation, with specific improvements including reduced fine lines maintaining 50-70% of treatment peak reduction, improved skin firmness and elasticity sustaining 40-60% of maximum improvement, better overall texture and appearance persisting at 50-80% of treatment levels, and completely resolved specific issues like scarring or hyperpigmentation staying improved
Any external links provided are for informational context only and do not imply endorsement